Cresemba® (isavuconazonium sulfate)

	Next higher product group	isavuconazole
	Status	2015-03-06 registration start
	Organisation	Astellas Pharma US Inc.
	Group	Astellas (Group)
	Organisation 2	Basilea Pharmaceutica Ltd. (SIX: BSLN)
	Group	Basilea (Group)

Record changed: 2023-07-10

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

More documents for antimycotic

[1] Novartis AG. (1/24/23). "Press Release: Sandoz Announces Agreement to Acquire Leading Antifungal Agent Mycamine from Astellas, Reinforcing Hospital Offering and Leading Anti-infectives Portfolio". Basel....
[2] F2G Ltd.. (8/4/22). "Press Release: F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Olorofim". Manchester....
[3] F2G Ltd.. (5/16/22). "Press Release: Shionogi Co., Ltd. and F2G Enter Strategic Collaboration to Develop and Commercialize the New Antifungal Agent Olorofim in Europe and Asia". Osaka & Manchester....
[4] Pulmocide Ltd.. (5/27/21). "Press Release: Pulmocide Raises $92 Million in a Series C Financing to Fund Registration Program for PC945". London....
[5] Jeito Capital. (5/27/21). "Press Release: Jeito Capital Leads Oversubscribed $92 million Series C Financing Round in Pulmocide". Paris....
[6] F2G Ltd.. (4/12/21). "Press Release: Francesco Maria Lavino Appointed Chief Executive Officer of F2G Ltd". Manchester & Vienna....
[7] Novo Holdings A/S. (8/12/20). "Press Release: Novo Ventures Portfolio Company F2G Closes US$60.8 Million Financing". Copenhagen....
[8] F2G Ltd.. (1/7/19). "Press Release: F2G Expands Investor Syndicate and Progresses Phase IIb Study for Novel Antifungal". Manchester....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]